Published in J Rheumatol on March 01, 2005
Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients | NCT00280917
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol (2011) 2.94
Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther (2005) 2.03
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology (2010) 1.70
Investigational A₃ adenosine receptor targeting agents. Expert Opin Investig Drugs (2011) 1.49
Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today (2011) 1.44
Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle. Circulation (2008) 1.24
The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther (2006) 1.09
Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res Ther (2006) 1.09
Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol (2008) 1.06
CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol (2011) 0.99
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol (2008) 0.99
Human lupus serum induces neutrophil-mediated organ damage in mice that is enabled by Mac-1 deficiency. J Immunol (2012) 0.98
Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res Ther (2006) 0.95
Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography. Nucl Med Biol (2009) 0.94
Mechanisms of induction of adenosine receptor genes and its functional significance. J Cell Physiol (2009) 0.92
A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol (2008) 0.91
Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb Exp Pharmacol (2009) 0.87
Enhanced neurodegeneration after a high dose of methamphetamine in adenosine A3 receptor null mutant mice. Neuroscience (2011) 0.85
Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol (2016) 0.83
The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol (2016) 0.82
Purinergic and calcium signaling in macrophage function and plasticity. Front Immunol (2014) 0.81
Intra-articular nuclear factor-κB blockade ameliorates collagen-induced arthritis in mice by eliciting regulatory T cells and macrophages. Clin Exp Immunol (2013) 0.78
Intracellular ATP concentration contributes to the cytotoxic and cytoprotective effects of adenosine. PLoS One (2013) 0.78
A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action. Mediators Inflamm (2014) 0.77
Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression. Purinergic Signal (2016) 0.75
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology (2010) 1.70
Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today (2011) 1.44
Talc inhalation is a life-threatening condition. Pathol Oncol Res (2004) 1.40
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol (2007) 1.38
The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res (2004) 1.36
Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene (2002) 1.21
Behçet's disease. Curr Opin Rheumatol (2008) 1.15
Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr (2004) 1.13
Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol (2007) 1.10
The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs (2007) 1.09
The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther (2006) 1.09
A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs (2002) 1.07
Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Mod Pathol (2008) 1.07
An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene (2004) 1.05
Identification of alpha-tropomyosin as a target self-antigen in Behçet's syndrome. Eur J Immunol (2002) 1.05
A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem (2003) 1.03
Pharmacology and therapeutic applications of A3 receptor subtype. Curr Top Med Chem (2003) 1.02
Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res (2003) 1.02
Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol (2002) 0.97
Pasteurella multocida infectious arthritis. Isr Med Assoc J (2004) 0.97
A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol (2003) 0.96
Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res Ther (2006) 0.95
Prevalence and clinical aspects of Behcet's disease in the north of Israel. Clin Rheumatol (2006) 0.95
An improved technique for mitosis counting. Int J Surg Pathol (2005) 0.94
Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med (2011) 0.92
Mid-term results of stapled hemorrhoidopexy for third- and fourth-degree hemorrhoids--correlation with the histological features of the resected tissue. World J Surg (2007) 0.90
Prognostic value of Topoisomerase II in female breast cancer. Oncol Rep (2004) 0.88
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist (2013) 0.86
Can hamartoma of the breast be distinguished from fibroadenoma using fine-needle aspiration cytology? Diagn Cytopathol (2006) 0.85
Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis. Neuroimmunomodulation (2012) 0.84
Small nucleolar RNA clusters in trypanosomatid Leptomonas collosoma. Genome organization, expression studies, and the potential role of sequences present upstream from the first repeated cluster. J Biol Chem (2003) 0.83
Enhancing pigmentation via activation of A3 adenosine receptors in B16 melanoma cells and in human skin explants. Exp Dermatol (2012) 0.83
Sex differences in the epidemiology, seasonal variation, and trends in the management of patients with acute appendicitis. Langenbecks Arch Surg (2012) 0.82
CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia (2005) 0.82
The role of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma. Am J Clin Pathol (2013) 0.81
Computerized analysis of cytology and fluorescence in situ hybridization (FISH) in induced sputum for lung cancer detection. Cancer Cytopathol (2010) 0.80
IVIg to prevent tumor metastases (Review). Int J Oncol (2002) 0.80
The HLA-B*5101 molecule-binding capacity to antigens used in animal models of Behçet's disease: a bioinformatics study. Isr Med Assoc J (2012) 0.80
Targeting the A3 adenosine receptor for glaucoma treatment (review). Mol Med Rep (2013) 0.79
Prevalence of Behcet's disease among adult patients consulting three major clinics in a Druze town in Israel. Clin Rheumatol (2010) 0.79
Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine. Purinergic Signal (2011) 0.79
Eisenbergiella tayi gen. nov., sp. nov., isolated from human blood. Int J Syst Evol Microbiol (2013) 0.78
A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int J Oncol (2002) 0.77
Vasculo-Behçet's disease. Isr Med Assoc J (2002) 0.76
Complementary suppression of T cell activation by peritoneal macrophages and CTLA-4-Ig. Immunobiology (2006) 0.76
Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer. Am J Clin Oncol (2016) 0.75
OS 05-04 EMPAGLIFLOZIN EXERTS CARDIO- AND NEPHRO-PROTECTIVE EFFECTS IN COHEN-ROSENTHAL DIABETIC HYPERTENSIVE RATS. J Hypertens (2016) 0.75
A new Ki-67 / E-cadherin cocktail reduces inter-observer variation of the calculated proliferative index. Pathol Oncol Res (2013) 0.75
Removable sinus stent for endoscopic sinus surgery: An animal trial. Am J Rhinol Allergy (2017) 0.75
Transthoracic needle biopsy in the diagnosis of large-cell neuroendocrine carcinoma of the lung. Diagn Cytopathol (2005) 0.75
OS 05-04 EMPAGLIFLOZIN EXERTS CARDIO- AND NEPHRO-PROTECTIVE EFFECTS IN COHEN-ROSENTHAL DIABETIC HYPERTENSIVE RATS. J Hypertens (2016) 0.75
Inflammatory arthritis of the hands as expressed by the impressionists in the Orsay Museum. J Clin Rheumatol (2004) 0.75
Ablation of experimental colon cancer by intratumoral 224Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy. Int J Radiat Biol (2015) 0.75
Huge uterine tumor in a postmenopausal woman. Arch Pathol Lab Med (2005) 0.75
Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial. J Drugs Dermatol (2016) 0.75